Jaguar Animal Health, Inc. (NASDAQ:JAGX) Sees Large Decrease in Short Interest

Jaguar Animal Health, Inc. (NASDAQ:JAGX) was the target of a large decrease in short interest in the month of May. As of May 15th, there was short interest totaling 67,479 shares, a decrease of 37.3% from the April 30th total of 107,543 shares. Currently, 18.5% of the shares of the company are sold short. Based on an average daily volume of 156,723 shares, the days-to-cover ratio is currently 0.4 days.

Jaguar Animal Health Stock Performance

Shares of NASDAQ JAGX opened at $2.96 on Thursday. The company has a current ratio of 0.50, a quick ratio of 0.30 and a debt-to-equity ratio of 4.08. Jaguar Animal Health has a 12-month low of $2.53 and a 12-month high of $144.55. The stock has a 50 day simple moving average of $8.73 and a 200-day simple moving average of $23.66. The company has a market cap of $1.78 million, a PE ratio of -0.01 and a beta of -0.09.

Jaguar Animal Health (NASDAQ:JAGX) last issued its quarterly earnings results on Wednesday, May 20th. The biotechnology company reported ($13.60) EPS for the quarter, beating analysts’ consensus estimates of ($149.10) by $135.50. Jaguar Animal Health had a negative return on equity of 1,194.94% and a negative net margin of 169.04%.The company had revenue of $20.27 million for the quarter, compared to analyst estimates of $4.21 million.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on JAGX shares. Wall Street Zen upgraded Jaguar Animal Health from a “sell” rating to a “hold” rating in a research note on Saturday, May 23rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Jaguar Animal Health in a research note on Tuesday, April 21st. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of “Sell”.

Jaguar Animal Health Company Profile

Jaguar Animal Health, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the gastrointestinal health of food-producing animals, with an emphasis on swine and poultry. The company’s research and development efforts target common enteric disorders such as post-weaning diarrhea in pigs and clostridial overgrowth in broiler chickens, aiming to provide effective alternatives to traditional antibiotic treatments.

Jaguar Animal Health was formed in early 2019 through the acquisition of the animal health business of Aratana Therapeutics by Actinium Animal Health, followed by a corporate rebranding.